Modulation of the physical state of cellular cholesteryl esters by 4,4'-(isopropylidenedithio)bis(2,6-di-t-butylphenol) (probucol).

[1]  S. Mao,et al.  Antioxidant activity of probucol and its analogues in hypercholesterolemic Watanabe rabbits. , 1991, Journal of medicinal chemistry.

[2]  S. Perkins,et al.  Structural changes in oxidised low-density lipoproteins and of the effect of the anti-atherosclerotic drug probucol observed by synchrotron X-ray and neutron solution scattering. , 1989, European journal of biochemistry.

[3]  H. Stanton,et al.  Influence of probucol on early experimental atherogenesis in hypercholesterolemic rats. , 1989, Atherosclerosis.

[4]  J L Witztum,et al.  Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. , 1989, The New England journal of medicine.

[5]  J L Witztum,et al.  Low density lipoprotein undergoes oxidative modification in vivo. , 1989, Proceedings of the National Academy of Sciences of the United States of America.

[6]  G. Rothblat,et al.  Triglyceride and cholesteryl ester hydrolysis in a cell culture model of smooth muscle foam cells. , 1989, Journal of lipid research.

[7]  L. McLean,et al.  Effect of probucol on the physical properties of low-density lipoproteins oxidized by copper. , 1989, Biochemistry.

[8]  J. Steinberg.  Book ReviewAmbulatory Pediatric Care , 1989 .

[9]  M. Phillips,et al.  Physical state of cholesteryl esters deposited in cultured macrophages. , 1988, Biochemistry.

[10]  L. McLean,et al.  Probucol reduces the rate of association of apolipoprotein C-III with dimyristoylphosphatidylcholine. , 1988, Biochimica et biophysica acta.

[11]  D. Small,et al.  George Lyman Duff memorial lecture. Progression and regression of atherosclerotic lesions. Insights from lipid physical biochemistry. , 1988, Arteriosclerosis.

[12]  T. Carew,et al.  Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[13]  A. Ooshima,et al.  Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[14]  T. Funahashi,et al.  Effects of probucol on xanthomata regression in familial hypercholesterolemia. , 1986, The American journal of cardiology.

[15]  J. Huttunen,et al.  Long-term use of probucol in the multifactorial primary prevention of vascular disease. , 1986, The American journal of cardiology.

[16]  S. Lamon,et al.  Effect of probucol treatment on lipoprotein cholesterol and drug levels in blood and lipoproteins in familial hypercholesterolemia. , 1986, Atherosclerosis.

[17]  J. Hamilton,et al.  Molecular motions and thermotropic phase behavior of cholesteryl esters with triolein. , 1985, Biochemistry.

[18]  B. Jacotot,et al.  The hypolipidemic action of probucol. Drug transport and lipoprotein composition in type IIa hyperlipoproteinemia. , 1985, Atherosclerosis.

[19]  M. Phillips,et al.  Lipid composition and physical state effects on cellular cholesteryl ester clearance. , 1984, Journal of Biological Chemistry.

[20]  T. Carew,et al.  A novel mechanism by which probucol lowers low density lipoprotein levels demonstrated in the LDL receptor-deficient rabbit. , 1984, Journal of lipid research.

[21]  S. Grundy,et al.  Influence of probucol on cholesterol and lipoprotein metabolism in man. , 1984, Journal of lipid research.

[22]  J L Witztum,et al.  Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[23]  M. Phillips,et al.  Cellular cholesteryl ester clearance. Relationship to the physical state of cholesteryl ester inclusions. , 1983, The Journal of biological chemistry.

[24]  Y. Matsuzawa,et al.  Effects of probucol on homozygous cases of familial hypercholesterolemia. , 1983, Atherosclerosis.

[25]  B. Lewis,et al.  The effects of probucol on plasma lipoproteins in polygenic and familial hypercholesterolaemia. , 1982, Atherosclerosis.

[26]  B. Joffe,et al.  Treatment of homozygous familial hypercholesterolaemia with probucol. , 1982, South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde.

[27]  W. Mantulin,et al.  Incorporation of defined cholesteryl esters into lipoproteins using cholesteryl ester-rich microemulsions. , 1982, The Journal of biological chemistry.

[28]  L. Simons,et al.  On the mechanism of plasma cholesterol reduction in the rat given probucol. , 1981, Clinical science.

[29]  P. Nestel,et al.  Effects of probucol on low density lipoprotein removal and high density lipoprotein synthesis. , 1981, Atherosclerosis.

[30]  M. Brown,et al.  The cholesteryl ester cycle in macrophage foam cells. Continual hydrolysis and re-esterification of cytoplasmic cholesteryl esters. , 1980, The Journal of biological chemistry.

[31]  B. Kottke,et al.  Effect of probucol on cholesterol metabolism in the rat. , 1980, Atherosclerosis.

[32]  J. A. Hamilton,et al.  Carbon-13 nuclear magnetic resonance studies of cholesteryl esters and cholesteryl ester/triglyceride mixtures. , 1977, The Journal of biological chemistry.

[33]  L. Arbogast,et al.  Cellular cholesterol ester accumulation induced by free cholesterol-rich lipid dispersions. , 1976, Proceedings of the National Academy of Sciences of the United States of America.

[34]  G. Shipley,et al.  Physical chemistry of the lipids of human atherosclerotic lesions. Demonstration of a lesion intermediate between fatty streaks and advanced plaques. , 1976, The Journal of clinical investigation.

[35]  R. S. Harris,et al.  Long‐Term Oral Administration of Probucol [4, 4‘‐(Isopropylidenedithio) bis (2, 6‐di‐t‐Butylphenol)] (DH‐581) in the Management of Hypercholesterolemia * , 1974, Journal of the American Geriatrics Society.

[36]  J. W. Barnhart,et al.  Hypocholesterolemic effect of 4,4'-(isopropylidenedithio)-bis(2,6-di-t-butylphenol) (probucol). , 1970, The American journal of clinical nutrition.

[37]  W. J. Dyer,et al.  A rapid method of total lipid extraction and purification. , 1959, Canadian journal of biochemistry and physiology.

[38]  F. B. Rosevear.  The microscopy of the liquid crystalline neat and middle phases of soaps and synthetic detergents , 1954 .